Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Bellicum Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Bellicum Pharmaceuticals yıllık ortalama 44.5% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.7% annual. Gelirler azalıyor .

Anahtar bilgiler

44.5%

Kazanç büyüme oranı

64.3%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-0.8%
Özkaynak getirisi	-486.1%
Net Marj	-1,484.0%
Son Kazanç Güncellemesi	30 Sep 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Aug 11

Bellicum launches $25M underwritten offering

Oct 29

Gelir ve Gider Dağılımı

Bellicum Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:BLCM Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 23	2	-22	7
30 Jun 23	2	-29	7
31 Mar 23	2	-25	6
31 Dec 22	2	-25	6
30 Sep 22	2	-16	6
30 Jun 22	6	-8	6
31 Mar 22	6	-6	6
31 Dec 21	6	-10	7
30 Sep 21	6	7	9
30 Jun 21	1	4	11
31 Mar 21	1	-37	13
31 Dec 20	1	-8	16
30 Sep 20	5	-55	18
30 Jun 20	5	-87	23
31 Mar 20	7	-70	27
31 Dec 19	7	-112	30
30 Sep 19	2	-111	31
30 Jun 19	3	-102	29
31 Mar 19	1	-100	27
31 Dec 18	1	-98	25
30 Sep 18	1	-93	23
30 Jun 18	1	-92	21
31 Mar 18	0	-93	21
31 Dec 17	0	-92	21
30 Sep 17	0	-90	20
30 Jun 17	0	-84	20
31 Mar 17	0	-76	19
31 Dec 16	0	-69	17
30 Sep 16	0	-66	17
30 Jun 16	0	-62	16
31 Mar 16	0	-56	15
31 Dec 15	0	-49	13
30 Sep 15	0	-106	11
30 Jun 15	1	-97	8
31 Mar 15	1	-90	6
31 Dec 14	2	-85	4
30 Sep 14	3	-14	3
30 Jun 14	3	-12	3
31 Mar 14	2	-10	3
31 Dec 13	2	-9	2

Kaliteli Kazançlar: BLCM şu anda kârlı değil.

Büyüyen Kar Marjı: BLCM şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BLCM kârlı değildir, ancak son 5 yılda zararlarını yılda 44.5% oranında azaltmıştır.

Büyüme Hızlandırma: BLCM 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BLCM kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BLCM hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -486.06% ) sahiptir.

Bellicum Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

Earnings released

Recent updates

Bellicum Pharmaceuticals Files Form 15

The University of Texas M. D. Anderson Cancer Center completed the acquisition of substantially all assets from Bellicum Pharmaceuticals, Inc. (OTCPK:BLCM).

Nasdaq to Delist the Common Stock of Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from NASDAQ Composite Index

Bellicum Pharmaceuticals Receives Written Notification from Nasdaq Regarding Listing Rule 5550(b)(1)

Consensus EPS estimates fall by 39%

Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer At ASCO GU Cancers Symposium

Bellicum Pharmaceuticals, Inc. Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

Price target decreased to US$5.00

Insufficient new directors

Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56

Bellicum Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$5.00

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Announces Board Changes

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Bellicum Pharmaceuticals, Inc. Provides an Operational Update

Full year 2020 earnings released: US$1.34 loss per share (vs US$24.01 loss in FY 2019)

Bellicum Pharmaceuticals, Inc. Reports Impairment for the Fourth Quarter Ended December 31, 2020

Bellicum Pharmaceuticals, Inc. Announces First Report Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

New 90-day high: US$4.65

Price target lowered to US$4.50

Bellicum Pharmaceuticals, Inc. Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell 2000 Dynamic Index

Bellicum Pharmaceuticals, Inc. Announces Resignation of David Strauss as Senior Director, Corporate Controller, and as the Company’s Principal Accounting Officer, Effective January 22, 2021

Bellicum Pharmaceuticals, Inc. Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

Bellicum Pharmaceuticals, Inc. Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

Bellicum Pharmaceuticals, Inc. to Reduce Staff by 2020

Bellicum launches $25M underwritten offering

Bellicum Pharmaceuticals, Inc. to Report Q4, 2018 Results on Mar 12, 2019

New 90-day low - US$6.28

Earnings released

The University of Texas MD Anderson Cancer Center completed the acquisition of certain assets of bio manufacturing facility and related laboratories from Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM).

Bellicum Pharmaceuticals, Inc.(NasdaqCM:BLCM) dropped from Russell Microcap Value Index

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin